Analgesics⏵
Antiandrogens⏵
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
Top
Results
All paxlovid studies
Meta analysis
 
Feedback
Home
←
next
study
→
previous
study
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Severe case -2% Improvement Relative Risk Discharge -6% Viral clearance 12% Paxlovid  Yu et al.  LATE TREATMENT  RCT Is late treatment with paxlovid beneficial for COVID-19? RCT 208 patients in China (April - June 2022) Trial compares with Huashi Baidu, results vs. placebo may differ Improved viral clearance with paxlovid (not stat. sig., p=0.33) c19early.org Yu et al., Phytomedicine, August 2023 Favors paxlovid Favors Huashi Baidu

Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial

Yu et al., Phytomedicine, doi:10.1016/j.phymed.2023.155025, ChiCTR2200059390
Aug 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
RCT 312 hospitalized COVID-19 patients in China, showing no significant difference between paxlovid and Huashi Baidu treatment. Combination therapy showed improved results to either treatment alone.
Important missing comments or errors? Let us know.
risk of severe case, 1.9% higher, RR 1.02, p = 1.00, treatment 3 of 103 (2.9%), control 3 of 105 (2.9%).
risk of no hospital discharge, 6.3% higher, RR 1.06, p = 0.78, treatment 49 of 103 (47.6%), control 47 of 105 (44.8%).
risk of no viral clearance, 12.0% lower, HR 0.88, p = 0.33, treatment 30 of 103 (29.1%), control 34 of 105 (32.4%), NNT 31.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yu et al., 16 Aug 2023, Randomized Controlled Trial, China, peer-reviewed, 18 authors, study period 18 April, 2022 - 5 June, 2022, this trial compares with another treatment - results may be better when compared to placebo, trial ChiCTR2200059390.
This PaperPaxlovidAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0